Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
{{output}}
Background: Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduc... ...
